骨形态发生蛋白与自体髂骨植骨在腰椎融合中的疗效与安全性比较:荟萃分析与系统综述
结果显示rhBMP组融合成功率更高(OR 3.79,95%CI 1.88-7.63,P=0.0002)、Oswestry功能障碍指数改善更优(均数差1.54,95%CI 0.18-2.89,P=0.03)、再手术率更低(OR 0.59,95%CI 0.43-0.80,P=0.0007),不良事件发生率无差异(OR 0.91,95%CI 0.70-1.18,P=0.47);亚组分析提示仅rhBMP-2优于ICBG。
要点
- rhBMP组融合成功率、ODI改善及再手术率均优于ICBG组。
- rhBMP与ICBG不良事件发生率无显著差异。
- 亚组分析显示仅rhBMP-2在腰椎融合中优于ICBG。
核心结论
- 在腰椎融合中,rhBMP-2显示出更高的融合成功率和更低的再手术风险。
- rhBMP(rhBMP-2和rhBMP-7)与ICBG的并发症发生率无差异。
- 建议将rhBMP尤其是rhBMP-2作为ICBG的有效替代用于腰椎融合。
研究设计与样本
- 系统文献综述与荟萃分析,检索PubMed、EMBASE和Cochrane Central Register of Controlled Trails的前瞻性随机对照试验。
- 采用GRADE方法对证据质量进行分级,证据等级为1级。
主要发现
- rhBMP组融合成功率更高(OR 3.79,95%CI 1.88-7.63,P=0.0002)。
- rhBMP组Oswestry功能障碍指数改善更优(均数差1.54,95%CI 0.18-2.89,P=0.03)。
- rhBMP组再手术率更低(OR 0.59,95%CI 0.43-0.80,P=0.0007)。
- 融合成功率存在明显异质性(I=58%),亚组分析提示仅rhBMP-2优于ICBG。
- rhBMP与ICBG不良事件发生率无差异(OR 0.91,95%CI 0.70-1.18,P=0.47)。
关键数值与推荐
- 融合成功率:OR 3.79,95%CI 1.88-7.63,P=0.0002,支持rhBMP组。
- Oswestry功能障碍指数改善:均数差1.54,95%CI 0.18-2.89,P=0.03,支持rhBMP组。
- 再手术率:OR 0.59,95%CI 0.43-0.80,P=0.0007,支持rhBMP组。
- 不良事件发生率:OR 0.91,95%CI 0.70-1.18,P=0.47,两组无差异。
临床怎么用
- 腰椎融合时可考虑使用rhBMP尤其是rhBMP-2作为ICBG的替代以提升融合成功率并降低再手术风险。
- rhBMP与ICBG并发症发生率无差异,选择时需结合具体临床情况。
- 亚组分析提示rhBMP-2优于ICBG,rhBMP-7的优越性未得到证实。
局限性
- 融合成功率存在明显异质性(I=58%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: This is a systematic literature review and meta-analysis. OBJECTIVE: We aimed to evaluate the efficacy and safety of recombinant human bone morphogenetic protein (RhBMP) and autologous iliac crest bone graft (ICBG) in lumbar fusion. SUMMARY OF BACKGROUND DATA: RhBMP has been emphasized in lumbar fusion due to high fusion success rate. However, ICBG remains the criterion standard graft approach for lumbar fusion. The safety and effectiveness of rhBMP are controversial. METHODS: Prospective randomized controlled trials were searched from PubMed, EMBASE, and Cochrane Central Register of Controlled Trails by using Medical Subject Headings terms "bone morphogenetic protein,' "bone transplantation,' and "spinal fusion.' Two independent investigators screened eligible studies, assessed the bias of original articles, extracted data including fusion success, Oswestry disability index improvement, improved short form 36 questionnaire scores, adverse events and re-operation, and a subgroup analysis. The GRADE approach was used to grade quality of evidence. RESULTS: Twenty randomized controlled trials (2185 patients) met the inclusion criteria. There were higher fusion success rate (odds ratio [OR] 3.79, 95% confidence interval [CI] 1.88-7.63, P = 0.0002), better improvement of Oswestry Disability Index (mean difference 1.54, 95% CI 0.18-2.89, P = 0.03), and lower re-operation rate (OR 0.59, 95% CI 0.43-0.80, P = 0.0007) in rhBMP group. Heterogeneity was obvious in fusion success rate (I = 58%); hence, a subgroup analysis, based on protein type (rhBMP-2 or rhBMP-7), was performed, which suggested that only rhBMP-2 was better than ICBG for lumbar fusion. There was no difference in the incidence of adverse events between rhBMP and ICBG (OR 0.91, 95% CI 0.70-1.18, P = 0.47). CONCLUSION: In lumbar fusion, rhBMP-2 exhibited a higher fusion success rate and reduced the risk of re-operation. No difference in complication rate is between rhBMP (rhBMP-2 and rhBMP-7) and ICBG. We suggest rhBMP especially rhBMP-2 as an effective substitute for ICBG for lumbar fusion. LEVEL OF EVIDENCE: 1.
引用
- Liu S, Wang Y, Liang Z, et al. Comparative Clinical Effectiveness and Safety of Bone Morphogenetic Protein Versus Autologous Iliac Crest Bone Graft in Lumbar Fusion: A Meta-analysis and Systematic Review. Spine (Phila Pa 1976). 2020. PMID: 31923133. doi:10.1097/BRS.0000000000003372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。